Live Breaking News & Updates on Molecular Therapeutic

Stay updated with breaking news from Molecular therapeutic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Cepheid Gets Health Canada License For Four-in-one Rapid Molecular Diagnostic Test


Cepheid Gets Health Canada License For Four-in-one Rapid Molecular Diagnostic Test
WASHINGTON (dpa-AFX) - Cepheid, a unit of Danaher Corp. (DHR), said Thursday that it has received a medical device license from Health Canada for Xpert Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic test for qualitative detection of the viruses causing COVID-19, Flu A, Flu B, and RSV infections from a single patient sample.
The test is now available in Canada and can be used in laboratories and at the point of care.
Cepheid noted that the four-in-one test is designed for use on any of the company s almost 30,000 GeneXpert Systems placed worldwide, with results delivered in approximately 36 minutes. ....

United States , David Persing , Danaher Corp , Health Canada , Danaher Corporation , Xpert Xpress , Expert Systems , Chief Medical , Technology Officer , ஒன்றுபட்டது மாநிலங்களில் , ட்யாநேஹர் கார்ப் , ஆரோக்கியம் கனடா , ட்யாநேஹர் நிறுவனம் , க்ஷ்பெற்ட் க்ஸ்ப்ரெஸ் , க்ஷ்பெற்ட் அமைப்புகள் , தலைமை மருத்துவ , தொழில்நுட்பம் அதிகாரி ,

Cardea Bio Takes In $6.5M More In Series A


socaltech.com
San Diego-based
Cardea Bio, a startup that is developing molecular biology equipment which uses semiconductors to analyze samples, said on Tuesday that it has raised $6.5M more in its Series A funding. The company said the new funding was led by 3E Bioventures Capital, and also included existing investors. The company has now raised $20M in its Series
The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please
login in order to access this members-only content, or ....

Cardea Bio , More In Series , Diego Based Cardea Bio , Bioventures Capital , கார்டியா உயிர் , மேலும் இல் தொடர் , டியாகோ அடிப்படையிலானது கார்டியா உயிர் ,

SPMC inaugurates P18-M molecular lab


January 10, 2021
THE Southern Philippines Medical Center (SPMC) inaugurated on Saturday, January 9, 2021, its P18-million molecular laboratory that could quadruple its testing capacity.
The facility was donated by the Metrobank Foundation (MBFI) and George Ty Foundation and constructed by the Ateneo de Davao University (AdDU). The facility was formally turned over to SPMC over the weekend.
The molecular facility will be conducting a real-time reverse transcription-polymerase chain reaction (RT-PCR) test of up to 200 samples a day, with a result turn-around time of three operating days.
Davao City Mayor Sara Duterte-Carpio, in a statement read by Assistant City Health Officer Dr. Marjorie Culas, said the new molecular laboratory will help improve the city government s testing efforts in its Covid-19 response. ....

Davao City , Marjorie Culas , Sara Duterte Carpio , Joel Tabora , Ricardo Audan , Southern Philippines Medical Center , Gt Foundation , Ateneo De Davao University Ad , Metrobank Foundation , George Ty Foundation , City Health , Philippines Medical Center , Ateneo De Davao University , City Mayor Sara Duterte Carpio , Assistant City Health Officer , Personal Protective Equipment , தவோ நகரம் , ஜோயல் தபோரா , ரிக்கார்டோ வுடன் , தெற்கு பிலிப்பைன்ஸ் மருத்துவ மையம் , க்ட் அடித்தளம் , அடேநேோ டி தவோ பல்கலைக்கழகம் விளம்பரம் , ஜார்ஜ் டி அடித்தளம் , நகரம் ஆரோக்கியம் , பிலிப்பைன்ஸ் மருத்துவ மையம் , அடேநேோ டி தவோ பல்கலைக்கழகம் ,

Viewpoint Molecular Targeting, Inc.: Viewpoint Molecular Targeting Announces Closing of Its Series A Financing with Proceeds of $13 Million


Viewpoint Molecular Targeting, Inc.: Viewpoint Molecular Targeting Announces Closing of Its Series A Financing with Proceeds of $13 Million
??
-NET into Phase 1 imaging studies beginning in 2021 and accelerate development of radioisotope production technologies
CORALVILLE, IA / ACCESSWIRE / January 8, 2021 / Viewpoint Molecular Targeting, Inc. ( Viewpoint or the Company ), a radiopharmaceutical company developing precision α-particle oncology
therapeutics and complementary diagnostic imaging agents, announced today it has closed the third and final tranche of its Series A financing for a total of approximately $13 million. Proceeds from the financing will be used to advance the Company s two lead programs, VMT01 and VMT-??-NET, into Phase 1 human clinical studies, further develop its proprietary VMT-??-GEN isotope generator, and fund general operating expenses. ....

Jenene Thomas , Kostenloser Wertpapierhandel , Michaelk Schultz , Frances Johnson , University Of Iowa , Viewpoint Molecular Targeting Inc , University Of Iowa Bioventures Center , Viewpoint Molecular Targeting , Chief Medical Officer , Chief Science Officer , Iowa Bioventures Center , Molecular Targeting , பிரான்சிஸ் ஜான்சன் , பல்கலைக்கழகம் ஆஃப் ஐயுவா , தலைமை மருத்துவ அதிகாரி , தலைமை அறிவியல் அதிகாரி ,